This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



diamorphine hydrochloride (Ayendi®)


Reference No. 2406

Publication date:
29/11/2019


Appraisal information

diamorphine hydrochloride (Ayendi®) 720 micrograms nasal spray
diamorphine hydrochloride (Ayendi®) 1600 micrograms nasal spray


Company: Wockhardt UK Ltd
BNF category: Central nervous system
NMG meeting date: 09/10/2019
AWMSG meeting date: 13/11/2019
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1719
Ratification by Welsh Government: 28/11/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Diamorphine hydrochloride (Ayendi®) is recommended as an option for use within NHS Wales for the treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Ayendi® nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with the appropriate monitoring.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download